NCT07668960
Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Eligibility criteria expanded, about 10 words
- Primary endpoints: details revised at 1 of 3 entries
- Start date changed from estimate of Jun 17, 2026 to Aug 26, 2026
- Secondary endpoints: details revised at 2 of 3 entries
- Study sites revised (4)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Phase I: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs); Incidence of dose limiting toxicity (DLT) events
Timeframe: within 5 weeks
Phase I: Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase II Dose (RP2D)
Timeframe: within 5 weeks
Phase IIa: The percentage of cervical lesions that have regressed to CIN1 or normal as confirmed by virology and histopathology
Timeframe: within 52 weeks
Secondary (3)
Phase I: The percentage of cervical lesions that have regressed to CIN1 or normal, as confirmed by virology and histopathology studies
Phase I&Phase IIa: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Phase I&Phase IIa: Percentage of HPV and E6E7 mRNA elimination
Arms and interventions
Arm of BBM-C101Experimental
Drugs: BBM-C101
Sites
4 sites in 1 country